FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:307-309 January 25, 2001 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lallemant, M. PubMed Citation

To the Editor: Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers.¹ Because mast cells are derived from hematopoietic stem cells,² we evaluated the therapeutic activity of cladribine in a patient with interferon alfa–resistant systemic mast-cell disease.

A 57-year-old man was given a diagnosis of systemic mast-cell disease in 1975. At that time, he presented with back pain due to multiple compression fractures of the vertebrae and urticaria pigmentosa. After treatment with spinal irradiation, the course of the patient's illness was indolent, although he continued to have skin lesions. In 1994, he had an episode of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Metcalfe, D. D. (2008). Mast cells and mastocytosis. Blood 112: 946-956 [Abstract] [Full Text]  
• Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M.-T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Mullauer, L., Agis, H., Sillaber, C., Valent, P. (2007). Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109: 3031-3041 [Abstract] [Full Text]  
• Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., Akin, C. (2006). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291 [Abstract] [Full Text]  
• O'Brien, S., Tefferi, A., Valent, P. (2004). Chronic Myelogenous Leukemia and Myeloproliferative Disease. ASH Education Book 2004: 146-162 [Abstract] [Full Text]  
• Kluin-Nelemans, H. C., Oldhoff, J. M., van Doormaal, J. J., van 't Wout, J. W., Verhoef, G., Gerrits, W. B. J., van Dobbenburgh, O. A., Pasmans, S. G., Fijnheer, R. (2003). Cladribine therapy for systemic mastocytosis. Blood 102: 4270-4276 [Abstract] [Full Text]